Navigation Links
Targeted Therapy Shows Promise Against Deadly Brain Cancer
Date:6/5/2010

Small trial found compound slowed drug-resistant medulloblastoma in children

SATURDAY, June 5 (HealthDay News) -- A preliminary study has found that a targeted treatment for medulloblastoma -- the most common malignant brain cancer in children -- may one day be able to treat drug-resistant forms of the disease.

"Less than 5 percent of patients currently survive medulloblastoma," said Dr. Amar Gajjar, lead author of the study, which was presented Saturday at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. "Most patients usually die 12 to 18 months after the tumor comes back."

Although this study was designed primarily to assess side effects, if the drug moves through the pharmaceutical pipeline, it would be the first targeted drug aimed at a signaling pathway. Chemotherapy is the main treatment now.

The drug, known as GDC-0449, interrupts the "sonic hedgehog" pathway, which has been implicated in a number of other cancers; it is involved in 20 percent of cases of children with medulloblastoma.

The drug has already been shown to have some effectiveness in adults with medulloblastoma that has recurred, as well as with basal cell carcinoma, a type of skin cancer.

Thirteen children with recurrent or drug-resistant brain tumors took GDC-0449 once a day for 28 days at one of two doses. The median age of the participants was about 12.

Twelve of the participants stayed the course without major side effects. One child was able to continue taking the drug for a full year without the cancer progressing.

"This demonstrates that we have taken a tumor, found a molecular subtype, found a drug which works, showed that it's safe in children and that we can have them benefit by treating these tumors using this molecular targeted therapy," said Gajjar, who is director of neuro-oncology in the department of oncology at St. Jude Children's Research Hospital in Memphis.

The research group will be moving on to a phase 2 trial. A phase 2 trial in adults is already ongoing, Gajjar said.

"Preliminary analysis has shown benefits to these [adult] patients," he noted.

Because this was such an early trial, "we don't yet know what impact this drug is going to have on survival," said Dr. Lynn Schuchter, moderator of a news conference involving the trial and a professor of medicine at the Abramson Cancer Center at the University of Pennsylvania. "We don't have a lot of data on follow-up, but this is really an amazing proof-of-principle idea and this pathway looks to be relevant in many cancers."

Schuchter reported ties to drug maker Pfizer Inc., while Gajjar reported no such ties.

More information

Children's Hospital Boston has more on medulloblastoma.



SOURCES: June 5, 2010, news conference with Lynn Schuchter, M.D., professor, medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, and Amar Gajjar, M.D., director, neuro-oncology division, department of oncology, St. Jude Children's Research Hospital, Memphis, Tenn.; June 5, 2010, American Society of Clinical Oncology annual meeting, Chicago


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Targeted Radiation for Early Breast Cancer a Good Option: Study
2. Blocking DNA repair protein could lead to targeted, safer cancer therapy
3. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
4. Women Smokers Targeted on World No Tobacco Day
5. Drug in new class of targeted therapies shows early promise against blood-related cancers
6. Site Steering Launches Keyword Targeted Small Business Internet Video Advertising Program That Achieves First Page Search Results Within Days
7. Gene-Targeted Therapy Might Help Prevent Paralysis
8. New targeted therapy effective in treating advanced prostate cancer
9. Kaiser Permanente Southern California to Offer FitOrbit Online Personal Training to Targeted Patients
10. Targeted agent blocked growth of deadly brain cancer in preclinical studies
11. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Dairy Products, Inc. in an upcoming episode, airing third quarter 2016 via Discovery ... churning cream into butter, Grassland Dairy Products, located in Greenwood, Wisconsin applies product ...
(Date:4/29/2016)... ... April 29, 2016 , ... The infertility specialists at HRC Fertility/Orange County ... Dr. Daniel A. Potter -- are proud of the recent release of their 2014 ... April, SART published the latest verified data for 375 U.S. member clinics. ...
(Date:4/29/2016)... ... 29, 2016 , ... International Dehydrated Foods, Inc. (IDF™) will attend and sponsor ... the Doubletree by Hilton Hotel in Oak Brook, Illinois. The two-day event is the ... protein ingredients. , At the seminar, IDF™ will offer samples of its Savory ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase ... period, and an increase of 1.2% on an adjusted pro ... first quarter were $0.52 reported, a decrease of 47.5% from ... 29.9% over the prior year period , The Company ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ...
(Date:4/28/2016)... April 28, 2016  ValGenesis, Inc., the ... Solutions (VLMS) today announced that a prominent ... sufferers of chronic kidney failure has selected ... their corporate validation process. The global medical ... solution to manage their validation processes electronically. ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 /PRNewswire/ ... des Sachs CEO Forums in Zürich gab ... ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung des ... eingesetzt wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie ... und Frankreich angeworben. STR001 wird während der ...
Breaking Medicine Technology: